Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poziotinib First-line in EGFR-mutated Lung Adenocarcinoma
NCT01819428Phase 2Terminated
- Sponsor
- National OncoVenture
- Start
- Mar 2013
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of poziotinib in lung adenocarcinoma, sponsored by National OncoVenture. Primary endpoint: Objective Response Rate at 3 years. Started Mar 2013; status: terminated.
02
Drugs
poziotinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT01819428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01819428.